4967.T Stock Today: Oasis Becomes Top Holder, AGM Showdown — December 28
Kobayashi Pharmaceutical stock (4967.T) closed at ¥5,269, down 1.29% today, as Oasis Management lifted its stake to 13.74% and became the largest shareholder after the red yeast supplement scandal. The move sets up a high-stakes March AGM where board changes may be proposed, raising the odds of an AGM proxy fight and a governance reset. Tokyo investors are weighing ownership shifts with fundamentals and technicals as headlines build into March, per Bloomberg’s report source.
Ownership shake-up and today’s price action
Kobayashi Pharmaceutical stock fell 1.29% to ¥5,269 (−¥69). Intraday range was ¥5,269 to ¥5,308 on volume of 219,100 versus a 234,649 average. Market cap stands at ¥398.0 billion. The price sits near the 50-day average of ¥5,263 and below the 200-day average of ¥5,367. Year to date change is −12.34%, with a 52-week range of ¥4,850 to ¥6,350.
Oasis Management’s 13.74% holding overtakes the founding family and signals more active engagement after the red yeast recall. This higher Oasis Management stake could press for board refresh and stronger oversight, a growing theme in Japan shareholder activism. Local reports confirmed the shift in control dynamics source.
What the March AGM could decide
The March meeting could bring proposals for more independent directors, clearer risk controls around health products, and tighter disclosure. Investors will also watch for capital return signals, including dividend policy or buybacks. If Kobayashi Pharmaceutical stock responds to credible reforms, the gap between brand strength and valuation risk may narrow.
An AGM proxy fight is possible if Oasis and allies seek board seats or governance changes. The outcome will hinge on proxy advisory opinions, retail turnout, and domestic institutions. For Kobayashi Pharmaceutical stock, vote math matters. Ordinary items are easier than structural changes, so investors should separate near-term board refresh hopes from deeper strategy shifts.
Valuation, balance sheet, and dividend
Kobayashi trades on 34.47x TTM earnings and 1.88x book, with price-to-sales at 2.44 and EV/sales at 2.17. Leverage is minimal: debt-to-equity is 0.0033 and net debt/EBITDA is −1.56. Liquidity is strong with a 3.12 current ratio and interest coverage of 969. These strengths can support changes, which is relevant as Kobayashi Pharmaceutical stock navigates governance debate.
Gross margin is 50.70%, operating margin 11.88%, and net margin 7.06%. EPS is ¥155.34. FY2024 saw pressure: revenue −4.53% year on year and EPS −49.50%. Dividend per share is ¥103, a 1.92% yield. For Kobayashi Pharmaceutical stock, sustainable margin recovery and steady cash returns will be key if the company pursues reforms after the supplement recall.
Technical levels and trading plan
RSI sits at 58.88, leaning constructive, while CCI at 208.68 signals overbought conditions. MACD histogram is positive at 11.62, but ADX is 10.04, suggesting no strong trend. Bollinger Bands show ¥5,188 lower, ¥5,262.50 middle, and ¥5,336.88 upper. ATR of 62.94 implies moderate daily swings for Kobayashi Pharmaceutical stock.
Watch the 50-day average near ¥5,263 and the lower band around ¥5,188 as support. Resistance appears near ¥5,337 and the ¥6,350 52-week high. Monitor volume versus the 234,649 average and MFI at 63.10 for demand signals. Next earnings is set for 10 Feb 2026, which sits after the AGM for Kobayashi Pharmaceutical stock.
Final Thoughts
Oasis’s 13.74% stake raises the chance of change at Kobayashi Pharmaceutical, with a March AGM likely to spotlight board composition, risk controls, and capital returns. Near term, we see a tug-of-war between technicals that are steady but not trending and a valuation that prices in quality while the business rebuilds after the recall. For traders, the ¥5,188 to ¥5,337 band frames risk, with the 50-day average as a pivot. For long-term investors, track margin recovery, governance actions, and any updates to the health products review. Kobayashi Pharmaceutical stock can re-rate if reforms land and earnings stabilize. As always, this is not advice. Do your own research.
FAQs
Oasis lifted its stake to 13.74% after the red yeast supplement recall raised questions about oversight and communication. That created an opening for change at the board level. Japan shareholder activism has grown, and a concentrated holder can influence proposals if other investors agree on governance and return priorities.
At ¥5,269, the stock trades at 34.47x TTM earnings, 1.88x book, and 2.44x sales. Balance sheet strength is clear, but FY2024 saw revenue and EPS decline. Value depends on confidence in a recovery and governance improvements. A sustained margin rebuild and stable cash returns would support the current multiple.
Investors may see proposals for more independent directors, stronger risk controls around health products, and a clearer capital return stance. If a proxy fight develops, board seats could shift. The market will weigh the credibility of reforms and the vote outcome when reassessing the stock’s risk and valuation.
Key supports are near the 50-day average around ¥5,263 and the Bollinger lower band near ¥5,188. Resistance sits near ¥5,337 and the 52-week high at ¥6,350. Watch volume versus the 234,649 average and momentum gauges like RSI 58.88 for confirmation of breakouts or fades.
Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.
